Business Context and Reporting Period
Company: Natural Alternatives International, Inc. (NAI)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: December 31, 2008 (Six months ended December 31, 2008)
Business Overview: NAI provides private label contract manufacturing services for nutritional supplements and distributes branded products. The company is currently undergoing a strategic shift to narrow its branded product focus, selling the legacy Real Health Laboratories (RHL) business (classified as discontinued operations) to concentrate on contract manufacturing and the "Pathway to Healing" product line.
Key Financial Metrics
| Metric (in thousands) | Six Months Ended Dec 31, 2008 | Six Months Ended Dec 31, 2007 |
|---|---|---|
| Net Sales | $37,142 | $41,287 |
| Gross Profit | $3,172 | $7,116 |
| Gross Margin | 8.5% | 17.2% |
| Operating Loss (Continuing Ops) | $(2,284) | $1,149 (Income) |
| Net Loss (Continuing Ops) | $(2,897) | $893 (Income) |
| Loss from Discontinued Ops | $(1,804) | $(650) |
| Total Net Loss | $(4,701) | $243 (Income) |
| Cash and Equivalents | $3,337 | $4,610 |
| Total Debt (Current + Long-term) | $5,532 | $2,730 (Prior Year End) |
| Working Capital Line Utilized | $3,538 | $0 |
Material Changes vs. Prior Period
- Revenue Decline: Net sales from continuing operations decreased 10.0% year-over-year. Private label contract manufacturing sales dropped 8.9% due to lower volumes from key customers and unfavorable foreign currency fluctuations. Branded product sales fell 31.7% due to the cessation of the Dr. Cherry television program.
- Margin Compression: Gross profit margin collapsed from 17.2% to 8.5%. This was driven by a shift in sales mix, incremental overhead expenses related to Good Manufacturing Practices (GMP) compliance, and higher labor costs.
- Restructuring and Discontinued Operations: The company recorded a $1.8 million loss from discontinued operations, primarily due to a $1.05 million charge for severance and exit costs associated with the sale of the legacy RHL business and operational consolidation.
- Cost Reduction: A new cost reduction program implemented in Q2 2009 resulted in a $558,000 charge but is expected to save approximately $3.6 million annually in operating overhead.
- Debt Increase: Total debt increased significantly to $5.5 million from $2.7 million at the prior fiscal year-end, driven by $3.5 million in borrowings against the working capital line of credit.
Guidance, Outlook, and Risks
- Outlook: Management expects reduced net sales and higher per-unit operating costs in the third quarter of fiscal 2009 due to economic conditions and reduced manufacturing throughput. However, these negative effects are expected to be partially offset by the recently implemented cost reduction program.
- Covenant Risk: The company does not expect to meet its fixed charge coverage ratio covenant as of March 31, 2009, due to cumulative losses and deferred tax asset valuation adjustments. Consequently, all long-term debt has been reclassified as current. Management intends to request a waiver from the lender, though no assurance is provided.
- Customer Concentration: Revenue remains highly concentrated. The two largest customers accounted for 77% of total sales from continuing operations for the six months ended December 31, 2008 (down from 81% in the prior year).
- Strategic Focus: Future efforts will focus on leveraging certified manufacturing facilities for private label customers, growing the "Pathway to Healing" line, and improving operational efficiencies.
Investor Verification Checklist
- Covenant Compliance: Verify the status of the waiver request for the fixed charge coverage ratio covenant due March 31, 2009, and the potential impact on debt classification and liquidity.
- Customer Concentration: Assess the stability of the top two customers, who represent the vast majority of revenue, and the risk of further volume declines.
- Discontinued Operations: Confirm the timeline and final terms for the sale of the remaining legacy RHL business operations.
- Cost Savings Realization: Monitor whether the projected $3.6 million in annual cost savings from the restructuring program is being realized as planned.
- Foreign Currency Impact: Evaluate the ongoing impact of Euro fluctuations on the European subsidiary (NAIE), which accounts for a significant portion of international sales.